Number of the records: 1  

New directions in the experimental therapy of tick-borne encephalitis

  1. 1.
    0572867 - BC 2024 RIV NL eng J - Journal Article
    Eyer, Luděk - Seley-Radtke, K. - Růžek, Daniel
    New directions in the experimental therapy of tick-borne encephalitis.
    Antiviral Research. Roč. 210, JAN (2023), č. článku 105504. ISSN 0166-3542. E-ISSN 1872-9096
    R&D Projects: GA ČR(CZ) GF21-05445L; GA ČR(CZ) GA20-14325S
    Institutional support: RVO:60077344
    Keywords : Tick-borne encephalitis * Tick-borne encephalitis virus * Antivirals * Monoclonal antibodies * Immunotherapy
    OECD category: Immunology
    Impact factor: 7.6, year: 2022
    Method of publishing: Limited access
    https://www.sciencedirect.com/science/article/pii/S016635422200273X?via%3Dihub

    Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. There is no specific therapy for the treatment of TBE patients. However, several efforts are being made to develop small molecules that specifically interfere with the life cycle of TBE virus. In particular, recently various nucleoside analogues that can inhibit the viral replicase, such as the RNA-dependent RNA polymerase or viral methyl-transferases, have been explored. In addition, human or chimeric (i.e., structural chimeras that combine mouse variable domains with human constant domains) monoclonal antibodies with promising potential for postexposure prophylaxis or early therapy have been developed. This review summarizes the latest directions and experimental approaches that may be used to combat TBE in humans.
    Permanent Link: https://hdl.handle.net/11104/0343708

     
     
Number of the records: 1  

  This site uses cookies to make them easier to browse. Learn more about how we use cookies.